



Radiotherapy and olaptosed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial

Frank A. Giordano¹, Julian P. Layer^{1,2}, Sonia Leonardelli², Lea L. Friker³, Clemens Seidel⁴, Christina Schaub⁵, Roberta Turiello², Elena Sperk⁶, Franziska Grau⁷, Daniel Paech⁷, Barbara Link¹, Wolf Mueller⁸, Ghazaleh Tabatabai⁹, Katharina Sahn¹⁰, Sied Kebir¹¹, Torsten Pietsch³, Martin Glas¹¹, Sotirios Bisdas¹², Ulrich Herrlinger⁵, Michael Hölzel²

¹ Department of Radiation Oncology, University Hospital Bonn; ² Institute of Experimental Oncology, University Hospital Bonn; ³ Department of Neuropathology, University Hospital Bonn; ⁴ Department of Radiotherapy, University Hospital Leipzig; ⁵ Department of Neurology, University Hospital Bonn; ⁶ Department of Radiation Oncology, University Hospital Mannheim, University of Heidelberg; ⁷ Department of Neuroradiology, University Hospital Bonn; ⁸ Institute of Neuropathology, University Hospital Leipzig; ⁹ Department of Neurology, University Hospital Tübingen; ¹⁰ Department of Neurology, University Hospital Mannheim, University of Heidelberg; ¹¹ Department of Neurology, University Hospital Essen; ¹² Department of Neuroradiology, National Hospital for Neurology London

1 BACKGROUND & STUDY DESIGN




Primary Endpoint: Safety as per # of patients with treatment-related CTCAE


Secondary Endpoints: NOX-A12 plasma levels, tumor vascularization/perfusion as per advanced MRI, PFS-6, mPFS, OS, QoL, NANO

Exploratory Endpoint: Translational characterization of TME response by CODEX®


2 SAFETY



3 EXEMPLARY COURSE



4 LESION RESPONSE




Radiotherapy + NOX-A12 in chemotherapy refractory GBM

Safe | No DLT | Promising clinical efficacy | T cell recruitment + clustering
Expansion arms with Bevacizumab or Pembrolizumab initiated



5 ADVANCED IMAGING



REGISTRATION & CONTACT

Registered with clinicaltrials.gov, ID: NCT04121455

Frank.Giordano@ukbonn.de

6 TUMOR MICROENVIRONMENT

